Prognostic Performance of the FLAMB Model in Primary Gastric Diffuse Large B-Cell Lymphoma
- 25 August 2025
- journal article
- Published by IMR Press in British Journal of Hospital Medicine
- Vol. 86 (8) , 1-19
Abstract
Aims/Background Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common gastrointestinal malignancy. While rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based regimens have improved survival, reliable prognostic tools remain scarce. The International Prognostic Index (IPI), though validated for nodal DLBCL, shows limited accuracy in PG-DLBCL. To address this, we developed an intelligent prognostic model integrating key clinical variables to optimize individualized risk stratification, particularly for resource-limited clinical settings. Methods A retrospective cohort study was conducted at Nanfang Hospital, Southern Medical University, enrolling patients diagnosed with PG-DLBCL between January 2007 and July 2022. Clinical data and survival outcomes were systematically collected. Optimal cut-off values were systematically determined for continuous variables using receiver operating characteristic (ROC) curve analysis. Survival rates were estimated using the Kaplan-Meier method, with survival curves plotted and univariate survival associations assessed using the log-rank test. Multivariable analyses were performed through Cox proportional hazards regression and random forest algorithms. A novel (ferritin, lactate dehydrogenase (LDH), age, monocyte count (mono), β2-microglobulin (β2-MG)) FLAMB prognostic model was constructed by integrating the Cox regression model with random forest classification. Model performance was evaluated by comparing its discriminative accuracy with that of the IPI scoring system. Results Statistically significant differences in 5-year survival among PG-DLBCL patients were observed for ferritin, age, mono, LDH, β2-MG, B symptoms, and cell of origin (COO) in univariate survival analysis (p < 0.05). We developed the FLAMB model using five routinely available variables (ferritin, LDH, age, mono, and β2-MG) to enhance risk stratification in PG-DLBCL. Compared to the IPI, FLAMB demonstrated superior discriminative power (C-index: 0.653 vs. 0.637, Δ = 1.6%) and more effectively identified high-risk patients requiring treatment intensification. This enhanced risk stratification was confirmed by a statistically significant log-rank test (p < 0.05). Survival analysis in subgroups of non-germinal center B-cell like (GCB) and B symptoms-negative patients yielded consistent results. Conclusion The newly developed FLAMB prognostic model offers more precise prognostic stratification than the IPI for patients with PG-DLBCL. FLAMB comprises five key variables derived from routine laboratory tests and general clinical characteristics, making it readily accessible. This model enables clinicians, particularly in primary care or community hospitals, to efficiently stratify patient risk, assess underlying disease severity, and inform timely treatment planning.Keywords
This publication has 31 references indexed in Scilit:
- Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell LymphomaHematological Oncology, 2025
- The future of immunotherapy for diffuse large B‐cell lymphomaInternational Journal of Cancer, 2024
- Tumour-associated macrophages in diffuse large B-cell lymphoma: the prognostic and therapeutic impact in a South African centre with high HIV seroprevalenceImmunologic Research, 2024
- Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphomaClinical and Experimental Medicine, 2024
- Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomasBlood Cancer Journal, 2024
- Treatment strategies for patients with diffuse large B-cell lymphomaCancer Treatment Reviews, 2022
- A systematic review of primary gastric diffuse large B-cell lymphoma: Clinical diagnosis, staging, treatment and prognostic factorsLeukemia Research, 2021
- Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPIBlood Reviews, 2018
- Racial differences in the presentation and outcomes of diffuse large B‐cell lymphoma in the United StatesCancer, 2010
- IL-6, monocyte infiltration and parenchymal cellsTrends in Immunology, 2003